Portal de Periódicos da CAPES

In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and Cefotaxime

2008; American Society for Microbiology; Volume: 52; Issue: 11 Linguagem: Inglês

10.1128/aac.00712-08

1098-6596

Asunción Fenoll, Lorenzo Aguilar, Olga Robledo, María-José Giménez, Juan-José Granizo, Donald Biek, David Tarragó,

Antimicrobial Resistance in Staphylococcus

In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates ExhibitingResistance to Penicillin, Amoxicillin, and Cefotaxime ᰔ Ten to forty percent of bacteremic pneumococcal infections occur in hospitalized patients, with the respiratory tract being the main portal of entry (2, 3).Empirical therapy of hospitalacquired pneumonia should cover Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) as "core pathogens" (1).This study explored the in vitro activity of ceftaroline, a parenteral anti-MRSA cephalosporin in phase 3 development, against S. pneumoniae isolates not susceptible to previous parenteral antimicrobials.Among the S. pneumoniae isolates received in the Spanish Pneumococcal Reference Laboratory (January 2005 to September 2007), 655 strains were selected.60 were nonsusceptible to penicillin, 250 to amoxicillin, and 170 to cefotaxime; 339 were resistant to erythromycin, and 152 were resistant to levofloxacin, according to current CLSI breakpoints (parenteral drugs/nonmeningitis) (5).Of these isolates, 337 (51.5%) were invasive (84.3% from bacteremia).Antimicrobial susceptibility was determined by agar dilution (4) in Mueller-Hinton agar (Difco Laboratories, Detroit, MI) TABLE 1. MIC 50 , MIC 90 , and percent susceptibility to study drugs for penicillin-nonsusceptible, amoxicillin-and cefotaxime-intermediate and -resistant, and erythromycin-and levofloxacin-resistant strains a Drug PEN-nonS (n ϭ 60) AMX-I (n ϭ 85) AMX-R (n ϭ 165) CTX-I (n ϭ 144) CTX-R (n ϭ 16) ERY-R (n ϭ 339) LVX-R (n ϭ 152)